These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23363626)

  • 1. Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces.
    Morgan SG; Thomson PA; Daw JR; Friesen MK
    BMC Health Serv Res; 2013 Jan; 13():34. PubMed ID: 23363626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers.
    Morgan SG; Thomson PA; Daw JR; Friesen MK
    Health Policy; 2013 Oct; 112(3):248-54. PubMed ID: 23809914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of product listing agreements by Canadian provincial drug benefit plans.
    Morgan SG; Friesen MK; Thomson PA; Daw JR
    Healthc Policy; 2013 May; 8(4):45-55. PubMed ID: 23968637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International best practices for negotiating 'reimbursement contracts' with price rebates from pharmaceutical companies.
    Morgan S; Daw J; Thomson P
    Health Aff (Millwood); 2013 Apr; 32(4):771-7. PubMed ID: 23569058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.
    Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C
    Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of drug reimbursement in Canada: the Pan-Canadian Pharmaceutical Alliance for new drugs.
    Husereau D; Dempster W; Blanchard A; Chambers J
    Value Health; 2014 Dec; 17(8):888-94. PubMed ID: 25498784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting improved patient outcomes using innovative product listing agreements: a survey of Canadian and international key opinion leaders.
    Thompson M; Henshall C; Garrison LP; Griffin AD; Coyle D; Long S; Khayat ZA; Anger DL; Yu R
    Clinicoecon Outcomes Res; 2016; 8():427-33. PubMed ID: 27616892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do provincial drug benefit initiatives create an effective policy lab? The evidence from Canada.
    Pomey MP; Morgan S; Church J; Forest PG; Lavis JN; McIntosh T; Smith N; Petrela J; Martin E; Dobson S
    J Health Polit Policy Law; 2010 Oct; 35(5):705-42. PubMed ID: 21123668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The timing of drug funding announcements relative to elections: a case study involving dementia medications.
    Gill SS; Gupta N; Bell CM; Rochon PA; Austin PC; Laupacis A
    PLoS One; 2013; 8(2):e56921. PubMed ID: 23460820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inter-provincial variation in government drug formularies.
    Grégoire JP; MacNeil P; Skilton K; Moisan J; Menon D; Jacobs P; McKenzie E; Ferguson B
    Can J Public Health; 2001; 92(4):307-12. PubMed ID: 11962119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Provincial drug plan officials' views of the Canadian drug safety system.
    Lexchin J; Wiktorowicz M; Moscou K; Eggertson L
    J Health Polit Policy Law; 2013 Jun; 38(3):545-71. PubMed ID: 23418364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
    Rawson NSB
    Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of health economic evaluation into immunization policy-making in Canada: Barriers and facilitators.
    Hopman HA; Crowcroft NS; Cesuroglu T; Langley JM
    Vaccine; 2020 Mar; 38(11):2512-2518. PubMed ID: 32057578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Universal prescription drug coverage in Canada: Long-promised yet undelivered.
    Morgan SG; Boothe K
    Healthc Manage Forum; 2016 Nov; 29(6):247-254. PubMed ID: 27744279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Real-World Data Sources for Canadian Drug Pricing and Reimbursement Decisions: Stakeholder Views and Lessons for Other Countries.
    Husereau D; Nason E; Ahuja T; Nikaï E; Tsakonas E; Jacobs P
    Int J Technol Assess Health Care; 2019 Jan; 35(3):181-188. PubMed ID: 31133089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pricing strategies, executive committee power and negotiation leverage in New Zealand's containment of public spending on pharmaceuticals.
    Main B; Csanadi M; Ozieranski P
    Health Econ Policy Law; 2022 Jul; 17(3):348-365. PubMed ID: 35382921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acceptability and feasibility of a national essential medicines list in Canada: a qualitative study of perceptions of decision-makers and policy stakeholders.
    Jarvis JD; Murphy A; Perel P; Persaud N
    CMAJ; 2019 Oct; 191(40):E1093-E1099. PubMed ID: 31591095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.